Nautilus Biotechnology, Inc. (NAUT) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Nautilus Biotechnology, Inc. (NAUT) stock forecast summary
Our AI ranks Nautilus Biotechnology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Nautilus Biotechnology, Inc. is a small-cap company with a market capitalization of $261M. It ranks number 15 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for NAUT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NAUT included.
Follow NAUT freeNAUT price chart and AI forecast
How NAUT ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Nautilus Biotechnology, Inc. (NAUT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | NAUT | Rank |
|---|---|---|
| Market Cap | $261M | 15/25 |
| P/B Ratio | 1.99x | 15/23 |
| EPS | $-0.46 | – |
| Book Value/Share | $1.03 | – |
| FCF/Share | $-0.41 | – |
Profitability & Margins
| Metric | NAUT | Rank |
|---|---|---|
| ROE | -43.1% | 15/21 |
| ROA | -34.5% | 17/22 |
Financial Health
| Metric | NAUT | Rank |
|---|---|---|
| Current Ratio | 10.14x | 4/25 |
| Quick Ratio | 10.07x | 3/24 |
| D/E Ratio | 0.25x | 19/24 |
| Financial Leverage | 1.25x | 19/24 |
| Working Capital | $79M | 17/25 |
Cash Flow
| Metric | NAUT | Rank |
|---|---|---|
| Operating Cash Flow | -$50M | 21/24 |
| Free Cash Flow | -$52M | 17/20 |
| Capital Spending | -$2M | 8/20 |
Income Statement
| Metric | NAUT | Rank |
|---|---|---|
| Net Income | -$56M | 14/22 |
| R&D Expense | $38M | 11/21 |
Dividend & Shareholder Information
| Metric | NAUT | Rank |
|---|---|---|
| Shares Outstanding | 127M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $88M | 53.6% of assets |
| Cash & Short-term Investments | $13M | 8.1% of assets |
| Inventory | $600K | 0.4% of assets |
| Total Liabilities | $32M | 19.8% of assets |
| Short-term Debt | $8M | 4.6% of assets |
NAUT quarterly financials and insider trading
Nautilus Biotechnology, Inc. (NAUT) industry peers
Companies classified under the same SEC industry code as Nautilus Biotechnology, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| A Agilent Technologies, Inc. | ▼ | $48.40B |
| WAT Waters Corp /De/ | ▲ | $42.17B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▼ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $250M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $117M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where NAUT sits on the market map
Nautilus Biotechnology, Inc. (NAUT) stock news
Loading...
Nautilus Biotechnology, Inc. (NAUT) stock forecast FAQ
What is the Nautilus Biotechnology, Inc. (NAUT) stock forecast?
Our AI ranks Nautilus Biotechnology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Nautilus Biotechnology, Inc. stock predictions?
A per-ticker accuracy statistic for NAUT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nautilus Biotechnology, Inc. forecasts updated?
Nautilus Biotechnology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Nautilus Biotechnology, Inc.'s industry peers?
25 issuers in our coverage, NAUT included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.